FibroBiologics presents CYPS317 preclinical psoriasis data showing durable immunomodulation

FibroBiologics, Inc.

FibroBiologics, Inc.

FBLG

0.00
  • FibroBiologics disclosed preclinical results for its CYPS317 psoriasis program that were presented at the Society for Investigative Dermatology 2026 Annual Meeting held May 13-15, 2026.
  • In mouse studies, a fibroblast spheroid formulation reduced psoriasis-like disease activity while avoiding systemic immune activation seen with single-cell delivery.
  • In a chronic-relapsing model, booster dosing helped sustain the treatment effect, supporting a repeat-dosing approach for longer-term disease control.
  • The data position CYPS317 as a potential differentiated, systemically administered cell therapy strategy for psoriasis, though it remains at the preclinical stage.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605220830PRIMZONEFULLFEED9724910) on May 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.